| Literature DB >> 12085263 |
J Yu1, W K Leung, M P A Ebert, E K W Ng, M Y Y Go, H B Wang, S C S Chung, P Malfertheiner, J J Y Sung.
Abstract
Survivin was recently described as an apoptosis inhibitor. Its pathogenic role in gastric cancer is largely unknown. Expression of survivin in gastric cancer and non-cancer first-degree relatives, and its association with apoptosis and cyclo-oxygenase-2 expression was investigated. Fifty gastric cancer, 30 non-cancer first-degree relatives, 20 normal controls and five gastric cancer cell lines were studied. Survivin and cyclo-oxygenase-2 were evaluated by reverse transcriptase-polymerase chain reaction, immunohistochemistry and Western blot. Survivin expression was absent from normal gastric mucosa. All five cancer cell lines and 34 out of 50 (68%) human gastric cancer tissues expressed survivin mRNA. Survivin expression was less frequent (22%; P<0.001) in adjacent non-tumour gastric tissues. Immunohistochemistry and Western blot obtained similar findings. Gastric cancers with survivin expression displayed significantly reduced apoptosis (P=0.02), and associated with cyclo-oxygenase-2 overexpression at both mRNA (P=0.001) and protein levels (P=0.041). Moreover, survivin mRNA was detected in the gastric mucosa of eight (27%) non-cancer relatives. Expression in non-cancer patients showed positive correlation with H. pylori infection (P=0.004). This demonstrates the frequent expression of survivin in gastric cancer and in first-degree relatives. Co-expression of survivin and cyclo-oxygenase-2 may suggest multiple pathways contributing to the inhibition of apoptosis in gastric cancer. Copyright 2002 Cancer Research UKEntities:
Mesh:
Substances:
Year: 2002 PMID: 12085263 PMCID: PMC2364284 DOI: 10.1038/sj.bjc.6600421
Source DB: PubMed Journal: Br J Cancer ISSN: 0007-0920 Impact factor: 7.640
Figure 1(A) Expression of survivin and COX-2 mRNA in gastric cancer cell lines (lane 1: NCI-N87; lane 2: MKN45), gastric cancer tissues (T) and paired non-tumour tissues (NT) (lanes 3–6), corpus (C) and antrum (A) biopsies of first-degree relatives (lanes 7–8) and non-cancer control (lanes 9–10). The 338 bp human survivin-specific sequence, 305 bp human COX-2-specific sequence and a 654 bp β-actin sequence were amplified from cDNA of gastric cancer cell lines and gastric tissues, separated by agarose gel electrophoresis and visualised by ethidium bromide staining. (B) Densitometry of survivin and COX-2 transcripts, standardised to β-actin, for the conditions listed above in A.
Figure 3(A) Representative samples of Western blotting for survivin and COX-2 proteins in human gastric cancer cell lines (KatoIII, AGS and MKN45), gastric cancer tissues (T), paired non-tumour tissues (NT) and control gastric mucosa (N). The upper panel represents the β-actin levels as the internal control. (B) Densitometry of survivin and COX-2 proteins, standardised to β-actin, for the conditions listed above in (A).
Figure 2(A) Staining of survivin was mainly restricted to tumour cells (short arrow) but was rarely in the adjacent normal mucosa in this sample (long arrow, ×250). (B) Apoptotic nuclei as revealed by TUNEL in survivin-positive tumour (long arrow, B1) and in survivin-negative tumour (long arrow, B2, ×250).
Cancer patients characteristics, clinical and molecular findings
Association between tumour expression of survivin mRNA and clinicopathological characteristic of patients with gastric cancer
Parameters of histological findings and mRNA expression in first degree relatives